New Israeli Med-Tech startup Acculine has developed a system that can determine if a person is at risk of having a heart attack. The firm, which previously received a grant from Google, just raised $4.2 million in seed funding to further develop its CORA system that can predict a cardio event.
Founded in 2022 by CEO Moshe Barel, Prof. Aharon Frimerman, head of the Interventional Cardiology unit at Hillel Yaffe Medical Center, Prof. Shai Revzen, a computer science professor at the University of Michigan, and CTO Benny Shani, AccuLine says that the firm wants to save millions of lives worldwide by preventing the next heart attack. AccuLine is developing CORA – an accurate, non-invasive, and cost-effective exam for early detection of CAD. AccuLine’s user-friendly exam includes a four-minute measurement of vital signs designed to replace inaccurate, time-consuming, and labor-intensive ergometry exams. This approach addresses the limitations of existing tools in accuracy, invasiveness, and cost. AccuLine has received grants from Google and the Israeli Innovation Authority, and among its shareholders are Mayo Clinic, eHealth Ventures and Maccabi Healthcare Services.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Acculine says that Explore CORA is an innovative system designed to assess a patient’s risk for coronary artery disease. Through a brief 4-minute evaluation of three vital signs – the heart’s electrical activity, oxygen saturation levels, and respiratory phase, CORA automatically generates results, ensuring a seamless and efficient process. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing health care-related costs.
According to the Centers for Disease Control and Prevention (CDC), someone in the United States suffers a heart attack every 40 seconds. The latest study from the Global Burden of Disease, published in 2019, states that cardiovascular disease is the number one cause of death globally, with approximately 18 million deaths annually, and according to the American Heart Association, coronary heart disease is the most common type of heart disease, killing over 382,000 people in the in 2020, in the United States.
“Diagnosing patients at very early stages of risk for CAD without invasive testing will add value to patinets, healthcare systems, doctors, and insurance organizations,” sad Moshe Barel, co-founder and CEO of AccuLine. “This test has the potential to save millions of lives a year and save hundreds of millions of dollars for healthcare systems on unnecessary tests or expensive treatments for patients after a heart attack, including rehabilitation and medication.”
